Leading into SRS 2018, Medicrea Highlights a New Study Showing That Patients Implanted with UNiD™ Patient-Specific Rods Are 2.6 Times More Likely to Be Optimally Corrected
LYON, France & NEW YORK--(BUSINESS WIRE)--Oct 10, 2018--The Medicrea ® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market – MRNTY & MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) proprietary software platform, services and technologies, announced today the publication of a new study validating the use of UNiD™ Patient-Specific Rods (PSR) for surgical correction of sagittal imbalance in adults.
Five years after its initial launch in September 2013, over 2,800 patients have benefited from UNiD™ ASI 100% proprietary pre-operative planning technologies and services associated with patient-specific spinal realignment rods, with a strong acceleration in adoption rate in 2018 especially in the USA (+62% cases year-to-date 2018 and +90% in Q3 2018).
Since its inception, the technology has supported surgeons specializing both in adult and pediatric indications with planning services and patient-specific implants focused on restoring sagittal and coronal alignment.
Federico Solla, M.D., Orthopaedic and Scoliosis Surgery Unit, Lenval Hospital, Nice, France and UNiD™ ASI user recently published the Article titled “Patient-Specific Rods for Surgical Correction of Sagittal Imbalance in Adults: Technical Aspects and Preliminary Results”. In this article, Federico Solla emphasizes the expected benefits of patient specific spinal care which include the optimal execution of the plan, decreased mechanical complications, and reduced operating time, no longer requiring the bending of rods during surgery.
This study demonstrates that the use of patient specific rods improves the correspondence between planning and surgical realization.
Evalina Burger, MD, Department of Orthopedics, University of Colorado SOM, Aurora, CO, co-author, stated that “these results support the use of the UNiD™ ASI platform to obtain the expected patient-specific sagittal balance with a special focus on the difference pelvic incidence (PI) – lumbar lordosis (LL).”
Medicrea’s proprietary UNiD™ ASI technology uses Artificial Intelligence that digests scientific data to generate intelligent surgical planning through machine learning while simultaneously allowing the Spine Surgeon to perform detailed, custom analyses of his cases. The entire clinical workflow is thus managed from start to finish through the UNiD™ comprehensive Platform.
Christopher Kleck, MD, Department of Orthopedics, University of Colorado SOM, Aurora, CO, co-author, added “With its proprietary UNiD™ ASI technology, Medicrea started revolutionizing the spine world by developing a model taking into consideration compensatory mechanisms to individually predict each patient’s outcomes.”
By simulating surgical strategies using proprietary data and algorithms taking into consideration patients’ optimal sagittal alignment and compensatory mechanisms, Medicrea produces a patient-specific rod industrially bent. This process preserves the rod’s full integrity, and limits stress points that could lead to rod fracture once implanted.
Vincent Fiere, MD, Spinal Unit, Santy Orthopaedic Center and Mermoz Hospital Ramsay GDA, Lyon, France, and co-author, concluded “With Medicrea’s breakthrough technology, we showed that patients implanted with UNiD™ PSRs were 2.6 times more likely to be optimally corrected.”
“We are extremely pleased to see an increasing number of publications focusing on the application of UNiD™ ASI in the treatment of complex spinal deformities” said Denys Sournac, Founder, Chairman and CEO of Medicrea. “A month ago, we concluded the first Artificial Intelligence focused meeting in Lyon with 20 international spine surgeons considered thought-leaders in their field. Medicrea Artificial Intelligence and Analytics (MAIA) was a success. A couple weeks ago, Jean-Luc Clement, MD, Fondation Lenval, Nice, France, published an Article validating our predictive modelling for AIS patients. Today, we are announcing another publication validating this technology for the adult population. The revolution is only starting, and we are looking forward to the surgeon community embracing the UNiD™ ASI technology to provide their patients with the best possible care.”
Click here to reach the article: Patient-specific Rods for Surgical Correction of Sagittal Imbalance in Adults: Technical Aspects and Preliminary Results - Solla, Federico, MD; Barrey, Cédric Y., MD, PhD; Burger, Evalina, MD; Kleck, Christopher J., MD; Fière, Vincent, MD
Click here to reach the article: Surgical increase in thoracic kyphosis increases unfused lumbar lordosis in selective fusion for thoracic adolescent idiopathic scoliosis - Jean-Luc Clément, MD; Yann Pelletier, MD; Federico Solla, MD; Virginie Rampal, MD
Through the lens of predictive medicine, Medicrea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 210 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D- printed titanium patient-specific implants.
For further information, please visit: Medicrea.com.
Medicrea is listed on EURONEXT Growth Paris ISIN: FR 0004178572 Ticker: ALMED LEI: 969500BR1CPTYMTJBA37
Medicrea is traded on OTCQX Best Market Tickers: MRNTY & MRNTF
View source version on businesswire.com:https://www.businesswire.com/news/home/20181010005774/en/
Founder, Chairman and CEO
Chief Financial Officer
Tel: +33 (0)4 72 01 87 87
KEYWORD: UNITED STATES EUROPE NORTH AMERICA FRANCE NEW YORK
INDUSTRY KEYWORD: SURGERY TECHNOLOGY DATA MANAGEMENT HARDWARE SOFTWARE HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH FDA SCIENCE
Copyright Business Wire 2018.
PUB: 10/10/2018 12:21 PM/DISC: 10/10/2018 12:21 PM